Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives $27.22 Consensus PT from Brokerages

Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) has been assigned an average rating of "Hold" from the nine ratings firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $26.67.

Several analysts recently weighed in on the company. Royal Bank of Canada restated a "sector perform" rating and set a $18.00 price objective on shares of Pacira BioSciences in a research report on Tuesday, January 14th. Truist Financial upgraded shares of Pacira BioSciences from a "sell" rating to a "hold" rating and raised their target price for the company from $8.00 to $25.00 in a research report on Thursday, January 30th. HC Wainwright boosted their price target on Pacira BioSciences from $48.00 to $65.00 and gave the stock a "buy" rating in a report on Tuesday. Needham & Company LLC reissued a "buy" rating and issued a $32.00 price objective on shares of Pacira BioSciences in a research note on Tuesday. Finally, Barclays upped their target price on Pacira BioSciences from $17.00 to $24.00 and gave the company an "overweight" rating in a report on Friday, February 28th.

Institutional Trading of Pacira BioSciences

Hedge funds have recently modified their holdings of the stock. Sterling Capital Management LLC grew its holdings in Pacira BioSciences by 779.4% in the fourth quarter. Sterling Capital Management LLC now owns 1,363 shares of the company's stock worth $26,000 after purchasing an additional 1,208 shares during the period. Ancora Advisors LLC acquired a new stake in shares of Pacira BioSciences in the 4th quarter valued at about $26,000. Caitlin John LLC increased its position in Pacira BioSciences by 1,850.0% in the 4th quarter. Caitlin John LLC now owns 1,872 shares of the company's stock valued at $35,000 after buying an additional 1,776 shares in the last quarter. Nisa Investment Advisors LLC raised its stake in Pacira BioSciences by 495.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company's stock worth $62,000 after buying an additional 2,749 shares during the period. Finally, PNC Financial Services Group Inc. boosted its holdings in Pacira BioSciences by 16.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company's stock worth $68,000 after acquiring an additional 513 shares in the last quarter. Institutional investors own 99.73% of the company's stock.

Pacira BioSciences Price Performance

NASDAQ:PCRX traded down $0.43 during mid-day trading on Friday, reaching $25.84. The stock had a trading volume of 2,731,586 shares, compared to its average volume of 964,763. The stock has a 50-day simple moving average of $24.82 and a two-hundred day simple moving average of $20.67. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89. Pacira BioSciences has a 12 month low of $11.16 and a 12 month high of $31.67. The stock has a market capitalization of $1.20 billion, a PE ratio of -12.73 and a beta of 0.71.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.